Program
vapendavir
Also written as “Vapendavir”, “VPV 1000 mg” and “vapendavir 132 mg capsule”.
Its studies are mostly in Enterovirus Infections · Pulmonary Disease, Chronic Obstructive · Asthma · Respiratory Tract Infections, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Altesa Biosciences | 41 open or running | phase 2since Oct 11, 2023 | Jun 7, 2023 | Nov 15, 2027phase 2 · NCT07610395 |
| Vaxart | 40 open or running | phase 2since Feb 13, 2015 | Mar 24, 2014 | none ahead |
| Biota Scientific Management Pty | 20 open or running | phase 2since Aug 3, 2010 | Aug 3, 2010 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 3, 2010First study: phase 2 study in RhinovirusNew to Biota Scientific Management PtyBiota Scientific Management Pty · NCT01175226 · 300 enrolled · United States
- Mar 24, 2014Vaxart's first study: phase 1 study in HealthyNew to VaxartVaxart · NCT02101866 · 36 enrolled · United States
- May 27, 2014Phase 1 study in Drug-Drug Interaction Healthy VolunteersBiota Scientific Management Pty · NCT02204501 · 24 enrolled · United States
- Feb 13, 2015Phase 2 study in AsthmaVaxart · NCT02367313 · 455 enrolled · United States, Bulgaria, Czechia and more
- Aug 15, 2016Phase 1 study in HealthyVaxart · NCT02877264 · 48 enrolled · United States
- Jan 12, 2017Phase 2 study in Respiratory Tract InfectionsVaxart · NCT03024177
- Jun 7, 2023Altesa Biosciences's first study: phase 1 study in Pulmonary Disease, Chronic ObstructiveNew to Altesa BiosciencesAltesa Biosciences · NCT05962645 · 21 enrolled · United States
- Oct 11, 2023Phase 2 study in Virus DiseasesAltesa Biosciences · NCT06149494 · 52 enrolled · United Kingdom
- Feb 11, 2025Phase 2 study in Healthy MalesAltesa Biosciences · NCT06834295 · 8 enrolled · United Kingdom
- May 12, 2026Phase 2 study in Rhinovirus InfectionAltesa Biosciences · NCT07610395 · 180 planned · United States, United Kingdom
Ahead
- Nov 15, 2027Primary completion: phase 2 study in Rhinovirus InfectionAltesa Biosciences · NCT07610395
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“VP1 capsid protein inhibitor”ChEMBL 37, by rule
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07610395Rhinovirus Infection · United States, United Kingdom | 2 | Recruiting | Altesa Biosciences | Nov 15, 2027 | 180 |
| NCT06834295Healthy Males · United Kingdom | 2 | Completed | Altesa Biosciences | Mar 23, 2025 | 8 |
| NCT06149494Virus Diseases · United Kingdom | 2 | Completed | Altesa Biosciences | Mar 30, 2025 | 52 |
| NCT05962645Pulmonary Disease, Chronic Obstructive · United States | 1 | Completed | Altesa Biosciences | Dec 12, 2023 | 21 |
| NCT03024177Respiratory Tract Infections | 2 | Withdrawn | Vaxart | Apr 2017 | 0 |
| NCT02877264Healthy · United States | 1 | Completed | Vaxart | Aug 2016 | 48 |
| NCT02367313Asthma · United States, Bulgaria, Czechia and more | 2 | Completed | Vaxart | Dec 2016 | 455 |
| NCT02204501Drug-Drug Interaction Healthy Volunteers · United States | 1 | Completed | Biota Scientific Management Pty | Jun 2014 | 24 |
| NCT02101866Healthy · United States | 1 | Completed | Vaxart | May 2014 | 36 |
| NCT01175226Rhinovirus · United States | 2 | Completed | Biota Scientific Management Pty | Mar 2012 | 300 |
How it is read
Names in the registry
- “Vapendavir”, 6 entries
- “VPV 1000 mg”, 1 entry
- “vapendavir 132 mg capsule”, 1 entry
- “vapendavir 264 mg tablet”, 1 entry
- “vapendavir 24 mg/mL oral suspension”, 1 entry
Conditions, from the studies’ own filings
- Enterovirus Infections, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
- Asthma, 1 study
- Respiratory Tract Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.